📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Ultimovacs

1.1 - Company Overview

Ultimovacs Logo

Ultimovacs

Headquarter: Norway
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of novel immunotherapies against cancer, including UV1, a peptide-based therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Offers TET vaccine adjuvant technology targeting antigen-presenting cells, and conducts clinical trials (INITIUM, NIPU, DOVACC, FOCUS) evaluating UV1 with checkpoint inhibitors across melanoma, mesothelioma, ovarian, and head and neck cancers.

Products and services

  • INITIUM trial: Ultimovacs conducts a Phase II study evaluating UV1 combined with checkpoint inhibitors for the treatment of metastatic malignant melanoma
  • TET technology: Ultimovacs engineers a targeted-delivery adjuvant technology ensuring antigen and adjuvant signals reach antigen-presenting cells, activating tumor-specific T cells
  • UV1: Ultimovacs develops a peptide-based therapeutic cancer vaccine that induces specific T-cell responses against telomerase, a universal antigen expressed in most types of cancer cells

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Ultimovacs

T3 Pharmaceuticals Logo

T3 Pharmaceuticals

HQ: Switzerland Website
  • Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
IntraOp Logo

IntraOp

HQ: United States Website
  • Description: Provider of compact, mobile electron therapy devices and platforms for cancer treatment, including Mobetron, a self-shielded electron-beam linear accelerator for intraoperative radiation therapy; FLASH-IQ, delivering UHDR electron beams for preclinical and investigational FLASH radiotherapy; and non-invasive electron therapy for non-melanoma skin cancer.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IntraOp company profile →
Bolt Biotherapeutics Logo

Bolt Biotherapeutics

HQ: United States Website
  • Description: Provider of a biotechnology platform for cancer immunotherapy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
Immedica Logo

Immedica

HQ: Sweden Website
  • Description: Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Immedica company profile →
BioImagene Logo

BioImagene

HQ: United States Website
  • Description: Provider of digital pathology solutions for clinical diagnostics and drug discovery, delivering integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories, including IHC algorithms such as HER2, ER/PR, and p53.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full BioImagene company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Ultimovacs

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Ultimovacs

2.2 - Growth funds investing in similar companies to Ultimovacs

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Ultimovacs

4.2 - Public trading comparable groups for Ultimovacs

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Ultimovacs

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Ultimovacs

What does Ultimovacs do?

Ultimovacs is a provider of novel immunotherapies against cancer, including UV1, a peptide-based therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Offers TET vaccine adjuvant technology targeting antigen-presenting cells, and conducts clinical trials (INITIUM, NIPU, DOVACC, FOCUS) evaluating UV1 with checkpoint inhibitors across melanoma, mesothelioma, ovarian, and head and neck cancers.

Who are Ultimovacs's competitors?

Ultimovacs's competitors and similar companies include T3 Pharmaceuticals, IntraOp, Bolt Biotherapeutics, Immedica, and BioImagene.

Where is Ultimovacs headquartered?

Ultimovacs is headquartered in Norway.

How many employees does Ultimovacs have?

Ultimovacs has 1,000 employees 🔒.

When was Ultimovacs founded?

Ultimovacs was founded in 2010 🔒.

What sector and industry vertical is Ultimovacs in?

Ultimovacs is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Ultimovacs

Who are the top strategic acquirers in Ultimovacs's sector and industry

Top strategic M&A buyers and acquirers in Ultimovacs's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Ultimovacs?

Top strategic M&A buyers groups and sectors for Ultimovacs include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Ultimovacs's sector and industry vertical

Which are the top PE firms investing in Ultimovacs's sector and industry vertical?

Top PE firms investing in Ultimovacs's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Ultimovacs's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Ultimovacs's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Ultimovacs's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Ultimovacs include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Ultimovacs's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Ultimovacs?

The key public trading comparables and valuation benchmarks for Ultimovacs include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Ultimovacs for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Ultimovacs with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Ultimovacs's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Ultimovacs with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Ultimovacs's' sector and industry vertical?

Access recent funding rounds and capital raises in Ultimovacs's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Ultimovacs